Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people lose somewhere between 1–2% of their body weight per month on Wegovy (semaglutide 2.4mg), with average total loss around 15% of starting weight over 68 weeks in clinical trials — published in the STEP 1 trial in the New England Journal of Medicine. That monthly figure varies considerably by dose stage, starting weight and lifestyle factors, and a prescriber assesses your individual picture before treatment begins. Wegovy is a prescription-only medicine; results shown here come from controlled clinical settings, not guaranteed outcomes.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks runs roughly like this: "I've read you lose about 1.5 kilos a month, so why am I only down half a kilo in week three?" The misconception is understandable. Averaging 15% total loss across 68 weeks produces a tidy monthly headline, but that average masks a very uneven curve.
In the STEP 1 trial, semaglutide 2.4mg produced around 15% average body-weight reduction, but most of that came in the second half of treatment once participants reached the full maintenance dose. The first several months are spent on lower titration steps (0.25mg, 0.5mg, 1.0mg, 1.7mg), each held for roughly four weeks, the body is adjusting, not yet at full therapeutic effect. Month-by-month patterns during the titration phase are typically modest; the faster losses come later.
The higher 7.2mg dose, approved by the MHRA in January 2026 and available as a dedicated single-dose pen from April 2026, showed around 20.7% average loss over 72 weeks in trials, approaching tirzepatide territory. Even so, if you want to understand what the average Wegovy weight loss per month actually looks like across the full dose schedule, the monthly rate is still shaped by where you are in the dose schedule. Total weight loss on Wegovy is a better long-term measure than any single month's figure. Individual results genuinely vary; no provider can promise you a specific monthly number.
UK private treatment prices for Wegovy are quoted per pen (one pen covers four weekly doses), so a monthly cost and a per-pen price are effectively the same thing. Since Eli Lilly's list-price revision in September 2025 pushed the market upward, reported private prices for semaglutide have typically ranged from around £149 to over £300 per month depending on dose and provider, figures that have been widely reported and which vary as supply and competition shift. If you want to understand what the average cost of Wegovy looks like across the market, treat any figure you read online as approximate and subject to change.
The more important question is what a quoted price actually includes. Many headline prices cover the medicine only. Consultation fees, prescription charges, delivery costs and any dose-review support can each be billed separately, turning a seemingly competitive monthly figure into a substantially higher real cost. The full picture of Wegovy's monthly cost explains exactly what to look for when comparing quotes.
At nume, the price you see includes the consultation, prescription, treatment and free next-working-day tracked delivery by DPD. We don't run discount codes or promotional pricing, not because we haven't thought about it, but because we chose a different model. Cheapest isn't a race we entered. If you want to see exactly what you would pay based on your BMI, your personalised Wegovy price is calculated on a dedicated page, not buried in a checkout flow.
Wegovy is a Prescription-Only Medicine. Under UK law, it can only be legally supplied following a clinical assessment by a registered prescriber. The MHRA's public guidance on GLP-1 medicines is explicit: these are not assessed for quick or cosmetic weight loss, and they carry real risks that a prescriber weighs against your individual health profile.
The MHRA has repeatedly warned about counterfeit and illegally traded weight-loss pens, in 2025 alone, enforcement operations seized roughly 20 million doses with an estimated street value of around £45 million, and a facility producing fake tirzepatide pens was raided in Northampton. Fake pens have contained the wrong substances entirely. Sellers offering these medicines without a prescription, through social media or with discount codes from unverified sources, are a red flag, report them via the Yellow Card scheme. You can check any online pharmacy's registration on the GPhC register.
Price is genuinely the wrong test for a prescription medicine. A small saving on the medicine itself is not the measure that keeps you safe, access to a genuine supply chain, a real prescriber who reviews your record, and someone to contact when you have questions are. Every order through nume is dispatched from our own GPhC-registered pharmacy after a named prescriber has reviewed it. How nume works sets out the full process.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.